StockNews.com Initiates Coverage on Global Cord Blood (NYSE:CO)

Research analysts at StockNews.com initiated coverage on shares of Global Cord Blood (NYSE:CO) in a research note issued to investors on Monday. The brokerage set a “strong-buy” rating on the medical research company’s stock.

Global Cord Blood Stock Performance

Shares of NYSE CO opened at $1.15 on Monday. The stock has a market capitalization of $139.78 million, a PE ratio of 1.80 and a beta of 0.16. Global Cord Blood has a twelve month low of $2.03 and a twelve month high of $5.50. The stock has a fifty day simple moving average of $0.96 and a 200-day simple moving average of $1.20.

Global Cord Blood Company Profile

Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants.